GLAXF
GSK plc
Next earnings Jul 28, 2026 · consensus $0.46 EPS, $8.48B rev
$25.77
▲ +1.74%$25.77▲ +44.73%
over 1Y
L $16.36H $30.97
Today+1.7%
1W+1.7%
1M+7.6%
3M-2.8%
YTD+11.0%
1Y+44.7%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 32 analysts
Buy
Mixed signals in the latest filings.
GSK plc shows limited reported revenue.
On these fundamentals, GLAXF screens as SELL on the SEC figures.
Is GLAXF a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 26 @ ~1.92 est
- Short put 23 @ ~0.69 est
debit $123max +$177max −$123BE 24.77
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$103B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-07-012026-07-01open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-262026-06-26open ↗SC TO-T/AFiling2026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-242026-06-24open ↗SC TO-TFiling2026-06-24open ↗6-KPeriod ending 2026-06-232026-06-23open ↗6-KPeriod ending 2026-06-222026-06-22open ↗11-KPeriod ending 2025-12-312026-06-17open ↗11-KPeriod ending 2025-12-312026-06-17open ↗
Frequently asked
- Is GSK plc (GLAXF) a buy?
- GLAXF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
Sources: SEC EDGAR (CIK 0001131399, latest 6-K filed 2026-07-01) · EODHD · as of 6/20/2026, 7:30:55 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 20, 2026, 3:30 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.